Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
This study is ongoing, but not recruiting participants.
Information provided by:
National Cancer Institute (NCI)
First received: August 6, 2003
Last updated: January 10, 2009
Last verified: May 2005
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|
Bécouarn Y, Senesse P, Thézenas S, Boucher E, Adenis A, Cany L, Jacob JH, Cvitkovic F, Montoto-Grillot C, Ychou M; Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Ann Oncol. 2007 Dec;18(12):2000-5.
Becouarn Y, Ychou M, Boucher E, et al.: A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (CPT-11 + oxaliplatin [IRINOX]) and two standard arms (LV5-FU2 + CPT-11 [FOLFIRI], LV5-FU2 + oxaliplatin [FOLFOX] in first line metastatic colorectal cancer (MCRC) (FNCLCC Accord 08). [Abstract] J Clin Oncol 24 (Suppl 18): A-3586, 2006.